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Abstract
Background and purpose: The use of involved field radiotherapy (IFRT) has generated concern about the
increasing incidence of elective nodal failure (ENF) in contrast to elective nodal irradiation (ENI). This meta-analysis
aimed to provide more reliable and up-to-date evidence on the incidence of ENF between IFRT and ENI.
Materials and methods: We searched three databases for eligible studies where locally advanced non-small cell lung
cancer (NSCLC) patients received IFRT or ENI. Outcome of interest was the incidence of ENF. The fixed-effects model
was used to pool outcomes across the studies.
Results: There were 3 RCTs and 3 cohort studies included with low risk of bias. There was no significant difference in
incidence of ENF between IFRT and ENI either among RCTs (RR = 1.38, 95 % CI: 0.59–3.25, p = 0.46) or among cohort
studies (RR = 0.99, 95 % CI: 0.46–2.10, p = 0.97). There was also no significant difference in incidence of ENF between
IFRT and ENI when RCTs and cohort studies were combined (RR = 1.15, 95 % CI: 0.65–2.01, p = 0.64). I2 of test
for heterogeneity was 0 %.
Conclusion: This meta-analysis provides more reliable and stable evidence that there is no significant difference in
incidence of ENF between IFRT and ENI.
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Introduction
Combination of chemotherapy and external beam radio-
therapy is the standard treatment for locally advanced
non-small cell lung cancer (NSCLC) patients. Tradition-
ally, external beam radiotherapy for patients with locally
advanced NSCLC targets the primary tumor as well as
the ipsilateral hilar and mediastinal nodal stations, and
sometimes the supraclavicular fossa nodal stations, even
if there is no evidence of clinical involvement of all
nodal stations. This technique is known as elective nodal
irradiation (ENI). However, ENI will limit dose escal-
ation because of pulmonary and esophageal toxicities,
and lower radiation dose is unfavorable to local tumor
control [1]. This calls for the omission of ENI and use of
another radiation treatment technique, which is called
involved field radiotherapy (IFRT). IFRT allows higher
radiation dose to the primary tumor with the goal of re-
ducing local failure.
However, the trend of using IFRT has generated con-
cern about the increasing incidence of nodal failure in
untreated nodal stations. Some studies reported the
crude incidences of elective nodal failure (ENF) were
below 10 % when IFRT were applied [2–4], particularly
in positron emission tomography-computed tomography
(PET-CT) staged patients [5, 6], while existing evidences
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for this were weak until now. Now the National Compre-
hensive Cancer Network (NCCN) guidelines recommend
IFRT omitting ENI is category 2A [7]. We, therefore, car-
ried out a systematic review and meta-analysis to provide
more reliable and up-to-date evidence on the incidence of
ENF between IFRT and ENI and to identify whether the
IFRT was as safe as reported.
Materials and methods
Study design
This was a systematic review carried out in accordance
with the Cochrane Collaboration Handbook for Systematic
Reviews of Interventions [8]. The manuscript was arranged
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) statement [9].
Search strategy
In order to achieve the maximum sensitivity, two review
authors (RJL and LY) independently searched through
the PubMed (1966 to February 2016), Embase (1988 to
February 2016), and Cochrane Central Register of Con-
trolled Trials (February 2016, Issue 2) databases to find
relevant articles using the following search strategy: (“Non-
small cell lung cancer” [all fields]) AND ( (“Involved field
radiotherapy” [all fields] OR “Involved field irradiation” [all
fields]) OR (“Elective nodal irradiation” [all fields] OR “Se-
lective nodal irradiation” [all fields])). The reference lists of
relevant articles were further explored manually.
Inclusion and exclusion criteria
According to the purpose of this meta-analysis, ENF was
defined as an uninvolved nodal failure without local fail-
ure, that is, any lymph nodes of failure in region only got
prophylactic irradiation in the ENI and corresponding re-
gion initially uninvolved in the IFRT. Failure in the unin-
volved lymph nodes that occurred with distant metastases
without local failure was also considered as ENF.
Only studies that investigated the locally advanced
NSCLC patients who received 3-dimensional conformal
or intensity modulated radiotherapy (concurrent chemo-
therapy, sequential chemotherapy, or not) with the use of
IFRT or ENI were eligible for inclusion in our meta-
analysis. Only the photon therapy was allowed. Studies
with no ENF data available, with single treatment arm and
containing less than 20 patients in each treatment arm
were excluded. Expert opinions, reviews, and letters were
excluded in case of publication bias. Besides, the studies
were limited to English publications in humans. All the ar-
ticles were filtered by inclusion and exclusion criteria.
Selection of studies and data collection
Three reviewers (SXL, XD and LXY) independently
assessed the eligibility of abstracts identified by the search.
The full article that appeared to meet the inclusion criteria
was retrieved for closer examination. Disagreement over
eligibility of a study was resolved by consensus. The meta-
analysis was performed to compare IFRT with ENI by esti-
mating the risk ratio (RR) of ENF. Our primary outcome
was the incidence of ENF. For each study, we extracted
the key information as following: first author’s name, year
of publication, number of patients, regimens for interven-
tion and control arms, duration of follow up, as well as
the incidence of ENF. According to the inclusion criteria,
only the data of locally advanced NSCLC patients were
eligible for extraction. If the data extraction of locally ad-
vanced was unable to be finished, the study was excluded.
Assessment of the risk of bias in included studies
Two reviewers (LNW and WYL) used the Cochrane risk
of bias table [8] to randomized controlled trial (RCT)
and the Newcastle-Ottawa Scale [10] to cohort study to
assess the risk of bias independently. Six domains were
employed in the Cochrane Collaboration guidelines in-
cluding random sequence generation, allocation conceal-
ment, blinding of participants or outcome assessment,
incomplete outcome data, selective outcome reporting,
and other sources of bias. The Newcastle-Ottawa Scale
assigned a maximum score of 4 for selection, 2 for com-
parability, and 3 for outcome. The quality score was
ranked as low (≤5 points) or high (≥6 points). As a result,
studies ranked as low quality level will be excluded. If ne-
cessary, a third reviewer (BSL) would solve disagreements.
Statistical analysis
We calculated the RR for dichotomous data with proper
algorithm. RR and 95 % confidence interval (CI) were
calculated for each study in an intent-to-treat analysis.
Heterogeneity across studies was assessed with a forest
plot and the inconsistency statistic (I2). If the heterogen-
eity was moderate or severe (I2 ≥ 50 %), a random-effects
analysis model would be applied; otherwise, the fixed-
effects analysis model would be applied. All calculations
were performed using Review Manager (version 5.3, the
Cochrane Collaboration). A 2-sided p < 0.05 was consid-
ered statistically significant. Graphical funnel plot was
generated to visually inspect for publication bias.
Results
Search results and characteristics of the included studies
A total of 277 potential articles were identified by the lit-
erature search; of these articles, 248 were filtered out
using our exclusion criteria after screening the titles and
abstracts. 29 studies were selected for further review.
After the intensive assessment and group discussion, 6
studies [11–16] were chosen for data extraction and
meta-analysis (Fig. 1). 3 of 6 studies were RCTs [11–13],
and the remaining three were cohort studies [14–16].
One study [15] included stage I-III patients, and only
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the data of stage III patients were eligible for extraction
according to the inclusion criteria. Furthermore, all the
patients of this study underwent PET-CT based radio-
therapy planning, which was not mandatory in other
studies. One study [14] included 10 stage IV oligometa-
static patients, but their oligometastatic lesions were
treated definitively, which had no effect on ENF. The
characteristics of these 6 studies were shown in Table 1.
Methodological quality of studies
All the 3 RCTs were classified as unclear risk of bias tak-
ing into account the lacking details of blinding of partic-
ipants and allocation concealment according to the
Cochrane risk of bias table. However, except for these
items, 3 RCTs were considered as low risk of bias. Based
on the Newcastle-Ottawa Scale to assess the risk of bias
of the 3 cohort studies, all of them were rated as a total
score of ≥7 points, which indicated a low risk of bias.
The methodological quality of the included studies was
presented in Additional files 1 and 2.
Meta-analysis of incidence of ENF
There were 3 RCTs and 3 cohort studies in the meta-
analysis. In RCTs, a total of 354 patients were assigned
for IFRT group (n = 174) versus ENI group (n = 180), and
the overall incidence of ENF was 6.9 % in the IFRT group
(12 incident cases) and 5.0 % in the ENI group (9 incident
cases). In cohort studies, 1147 patients were assigned for
IFRT group (n = 226) versus ENI group (n = 921), and the
overall incidence of ENF was 4.4 % in the IFRT group
(10 incident cases) and 3.0 % in the ENI group (28
incident cases). There was no significant difference in
incidence of ENF between IFRT and ENI either
among RCTs (RR = 1.38, 95 % CI: 0.59–3.25, p = 0.46;
Fig. 2) or among cohort studies (RR = 0.99, 95 % CI:
0.46–2.10, p = 0.97; Fig. 2) assuming a fixed-effects
model. When combining RCTs with cohort studies, a
total of 1501 patients were assigned for IFRT group
(n = 400) versus ENI group (n = 1101), and the overall in-
cidence of ENF was 5.5 % in the IFRT group (22 incident
cases) and 3.4 % in the ENI group (37 incident cases).
There was no significant difference in incidence of ENF
Fig. 1 Selection and evaluation process of the eligible studies
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Table 1 Characteristics of included studies
Study Years of inclusion Study arms Patients (n) RT dose Chemotherapy Follow-up time (months) Number of ENF
RCTs
Yuan 2007 1997–2001 IFRT 100 68-74Gy Concurrent 27 (median) 7
ENI 100 60-64Gy 27 (median) 4
Yang 2007 2002–2004 IFRT 29 66-74Gy Sequential Till December 2005 3
ENI 26 56-70Gy Till December 2005 1
Chen 2013 2002–2011 IFRT 45 38-74Gy Concurrent 14.1 (median) 2
ENI 54 32-70Gy 14.1 (median) 4
Cohort studies
Fernandes 2010 2003–2008 IFRT 48 60-84Gy Concurrent or sequential 13.5 (median) 6
ENI 60 54-72Gy 17 (median) 7
Kolodziejczyk 2012 2008–2009 IFRT 35 58.8Gy Sequential 32 (median) 1
ENI 17 58.8Gy 32 (median) 0
Topkan 2015 2007–2012 IFRT 143 60–66Gy Concurrent 23.3 (median) 3
ENI 844 60–66Gy 23.3 (median) 21
Note: IFRT involved field radiotherapy, ENI elective nodal irradiation, ENF elective nodal failure, Gy gray
Fig. 2 Meta-analysis of incidence of ENF between IFRT and ENI
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between IFRT and ENI assuming a fixed-effects model
(RR = 1.15, 95 % CI: 0.65–2.01, p = 0.64; Fig. 2). Further-
more, there were no evidence of heterogeneity among 3
RCTs (Chi2 = 1.48, p = 0.48, I2 = 0 %; Fig. 2), 3 cohort stud-
ies (Chi2 = 0.16, p = 0.92, I2 = 0 %; Fig. 2), and all the in-
cluded studies (Chi2 = 1.95, p = 0.86, I2 = 0 %; Fig. 2).
Publication bias
We had applied sensitive search strategies and rigorous
inclusion criteria to minimize the potential publication
bias. According to the funnel plot, no significant asym-
metry was detected for our outcome (Fig. 3).
Discussion
Radiotherapy with ENI has been used since the 2-
dimensional radiotherapy era for the improvement of pa-
tient’s local control and survival. But emerging evidences
from RTOG trials showed that elective irradiation of me-
diastinal, contralateral hilar and supraclavicular lymph
nodes may not be necessary in the treatment of unresect-
able NSCLC [17]. In addition, the rate of ENF was really
low in clinical practice without ENI [2–6]. Thus, more
and more treatment guidelines [7, 18] do not recommend
the use of ENI in NSCLC. We believe that it may be at-
tributed to the following reasons: (1) The development of
3-dimensional conformal and intensity modulated radio-
therapy techniques enable dose escalation especially in use
of IFRT, and dose escalation is no doubt favorable to local
control [19, 20]. Moreover, IFRT can reduce toxicity by
virtue of a decrease in radiation volume. (2) Higher sensi-
tivity of imaging for involved lymph nodes, especially the
use of PET-CT [21], which is supposed to lead to
better radiation volume tailoring [22]. (3) Concurrent
or sequential use of chemotherapy with radiotherapy
may also help control local diseases. (4) Although the
elective nodal regions are not included in IFRT, they
are incidentally irradiated with prophylactic doses,
and the prophylactic doses may contribute to the low
incidence of ENF [23–26]. Before this meta-analysis,
despite the widespread abandoning of ENI for NSCLC
patients, we still take a conservative approach in our
department because existing evidence for this is insuf-
ficient. It consists of only three small RCTs and three
cohort studies. We believe that meta-analysis can
serve as a valuable tool for studying rare and unin-
tended effects of a treatment, and it can extend prior
randomized and nonrandomized studies by permitting
synthesis of data and providing more stable estimate
of effect. Based on the above, we decided to carry out
this meta-analysis.
In this meta-analysis, there were three RCTs and three
cohort studies. There was no significant difference in in-
cidence of ENF between IFRT and ENI either among
RCTs (RR = 1.38, 95 % CI: 0.59–3.25, p = 0.46) or among
cohort studies (RR = 0.99, 95 % CI: 0.46–2.10, p = 0.97)
assuming a fixed-effects model. The Cochran’s Q test re-
sulted in a p = 0.48 and a p = 0.92 respectively, and the
quantity I2 both were 0 %, indicating that the studies
were homogeneous. So we performed a combined ana-
lysis of RCTs and cohort studies, and there was also no
significant difference in incidence of ENF between IFRT
and ENI assuming a fixed-effects model (RR = 1.15, 95 %
Fig. 3 Funnel plot of included studies for primary outcome
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CI: 0.65–2.01, p = 0.64). The quantity I2 was also 0 %, in-
dicating that there was no evidence of heterogeneity
among all the included studies.
Our meta-analysis demonstrated that the difference in
incidence of ENF was not significant between IFRT and
ENI. This meta-analysis had two main strengths. Firstly, it
summarized the highest quality data available comparing
IFRT with ENI for locally advanced NSCLC patients until
now. Secondly, there was no heterogeneity in the results
of the included studies. Nevertheless, this meta-analysis
had several limitations. Firstly, the quality of the data was
different. For example, this meta-analysis included three
cohort studies, which lacked the experimental random al-
location of the intervention in contrast to RCTs. Secondly,
we compared outcomes across studies but not within
studies, so the balance of baseline characteristics between
the treatment groups might be neglected. For example,
the IFRT group received higher radiation doses than the
ENI group in most studies, and statistical analysis showed
that the difference was significant in some studies [12, 14].
Thirdly, the follow-up time was relatively short in some
studies [13], and some patients might have not suffered
from ENF or have died before they suffered from ENF.
Conclusion
To the best of our knowledge, this is the first meta-
analysis of published studies to evaluate the difference in
incidence of ENF between IFRT and ENI. It provides
more reliable and stable evidence that there is no signifi-
cant difference in incidence of ENF between IFRT and
ENI. IFRT will inevitably take the place of ENI.
Additional files
Additional file 1: Figure S1. Quality assessment of RCTs using the
Cochrane risk of bias table. (DOC 28 kb)
Additional file 2: Table S1. Quality assessment of cohort studies using
the Newcastle–Ottawa scale. (DOC 26 kb)
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